FindTrial
Sign In

Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00634400
Enrollment
6268
Registered
2008-03-13
Start date
1999-03-31
Completion date
2003-05-31
Last updated
2011-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure

Keywords

Congestive Heart Failure, Atacand, Candesartan

Brief summary

A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function

Interventions

DRUGCandesartan
DRUGPlacebo

Sponsors

AstraZeneca
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Male or female aged 18 or above * Congestive Heart Failure with symptoms for more than 4 weeks before starting study * Provision of informed consent

Exclusion criteria

* Current low blood pressure with symptoms * Liver disease considered significant by the study doctor * Pregnant or lactating females

Design outcomes

Primary

MeasureTime frame
Cardiovascular mortality or hospitalisation due to congestive heart failure2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months

Secondary

MeasureTime frame
Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026